CJC Open最新文献

{"title":"Reply to Albulushi et al.—Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From RHAPSODY Long-term Extension","authors":"","doi":"10.1016/j.cjco.2024.05.014","DOIUrl":"10.1016/j.cjco.2024.05.014","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24002518/pdfft?md5=b5e313b61cdd7fef9d20bf615416ceb0&pid=1-s2.0-S2589790X24002518-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141409303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Interrupted Time-Series Analysis of the Impact of COVID-19 on Hospitalizations for Vascular Events in 3 Canadian Provinces","authors":"","doi":"10.1016/j.cjco.2024.04.010","DOIUrl":"10.1016/j.cjco.2024.04.010","url":null,"abstract":"<div><h3>Background</h3><p>COVID-19 infection is associated with a pro-coagulable state, thrombosis, and cardiovascular events. However, its impact on population-based rates of vascular events is less well understood. We studied temporal trends in hospitalizations for stroke and myocardial infarction in 3 Canadian provinces (Alberta, Ontario, and Nova Scotia) between 2014 and 2022.</p></div><div><h3>Methods</h3><p>Linked administrative data from each province were used to identify admissions for ischemic stroke, intracerebral hemorrhage, cerebral venous thrombosis, and myocardial infarction. Event rates per 100,000/quarter, standardized to the 2016 Canadian population, were calculated. We assessed changes from quarterly rates pre-pandemic (2014-2020), compared to rates in the pandemic period (2020-2022), using interrupted time-series analysis with a jump discontinuity at pandemic onset. Age group– and sex-stratified analyses also were performed.</p></div><div><h3>Results</h3><p>We identified 162,497 strokes and 243,182 myocardial infarctions. At pandemic onset, no significant step change in strokesper 100,000/quarter was observed in any of the 3 provinces. During the pandemic, stroke rates were stable in Alberta and Ontario, but they increased in Nova Scotia (0.44 per 100,000/quarter, <em>P</em> = 0.004). At pandemic onset, a significant step decrease occurred in myocardial infarctions per 100,000/quarter in Alberta (4.72, <em>P</em> &lt; 0.001) and Ontario (4.84, <em>P</em> &lt; 0.001), but not in Nova Scotia. During the pandemic, myocardial infarctions per 100,000/quarter decreased in Alberta (–0.34, <em>P</em> = 0.01), but they remained stable in Ontario and Nova Scotia. No consistent patterns by age group or sex were noted.</p></div><div><h3>Conclusions</h3><p>Hospitalization rates for stroke or myocardial infarction across 3 Canadian provinces did not increase substantially during the first 2 years of the pandemic. Continued surveillance is warranted as the virus becomes endemic.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X2400180X/pdfft?md5=bb0f9f9f85ec2cef6766926996bf11aa&pid=1-s2.0-S2589790X2400180X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141952323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Transesophageal Echocardiography Appropriateness for Diagnosing Infective Endocarditis: Insights From Two Tertiary-Care Hospitals","authors":"","doi":"10.1016/j.cjco.2024.04.008","DOIUrl":"10.1016/j.cjco.2024.04.008","url":null,"abstract":"<div><h3>Background</h3><p>Echocardiography plays a key role in the diagnosis of infective endocarditis (IE), and recommendations have been published regarding the appropriate use of transesophageal echocardiography (TEE). The objective of this study is to evaluate the utilization of TEE in Regina, Saskatchewan, in the diagnosis of IE.</p></div><div><h3>Methods</h3><p>A retrospective chart review was performed on patients aged ≥ 18 years who received a TEE test for the diagnosis of IE from January 1 to December 31, 2019. The primary outcome included the proportion of TEE uses that complied with the American College of Cardiology Foundation and American Society of Echocardiography (ACCF and ASE) recommendations and the European Society of Cardiology (ESC) recommendations.</p></div><div><h3>Results</h3><p>A total of 204 admissions involving 188 patients who had TEE performed for the diagnosis of IE occurred within the study period. The mean age was 53.1 ± 17.1 years. Of the 204 TEE uses, 152 (74.5%) were considered appropriate by the ACCF and ASE recommendations. Having at least one predisposing condition (adjusted odds ratio [aOR] 4.30 [95% confidence interval [CI] 2.11-9.04), <em>P</em> &lt; 0.001]) was more likely to be associated with appropriate TEE use, per the ACCF and ASE criteria. Of the 204 TEE uses, only 80 (39.2%) were considered appropriate by the ESC recommendations. Having a history of intravenous drug use (aOR 3.08 [95% CI 1.08-9.27], <em>P</em> = 0.04) and having blood cultures positive for IE-related organisms (aOR 2.31 [95% CI 1.16-4.80], <em>P</em> = 0.02)) were more likely to be associated with appropriate TEE use, per ESC recommendations.</p></div><div><h3>Conclusions</h3><p>The current study suggests that the use of TEE in the diagnosis of IE demonstrated variable levels of adherence to recommendations published by the ACCF and ASE and by the ESC, with significant discrepancy between the two.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001781/pdfft?md5=37cffd7a7058f685bc98db10a4e2e6be&pid=1-s2.0-S2589790X24001781-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141952297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality Imaging of Acute Myocarditis in Cytokine Release Syndrome (CRS) Following CAR-T Therapy","authors":"","doi":"10.1016/j.cjco.2024.04.004","DOIUrl":"10.1016/j.cjco.2024.04.004","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001732/pdfft?md5=b7d2b98c7bfde793621f6d47d8f5c332&pid=1-s2.0-S2589790X24001732-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Innovative Patient-Centred Approach to Heart Failure Management: The Best Care Heart Failure Integrated Disease-Management Program","authors":"","doi":"10.1016/j.cjco.2024.03.015","DOIUrl":"10.1016/j.cjco.2024.03.015","url":null,"abstract":"<div><h3>Background</h3><p>The management of heart failure (HF) is challenging because of the complexities in recommended therapies. Integrated disease management (IDM) is an effective model, promoting guideline-directed care, but the impact of IDM in the community setting requires further evaluation.</p></div><div><h3>Methods</h3><p>A retrospective evaluation of community-based IDM. Patient characteristics were described, and outcomes using a pre- and post-intervention design were HF-related health-service use, quality of life, and concordance with guideline-directed medical therapy (GDMT).</p></div><div><h3>Results</h3><p>715 patients were treated in the program (2016 to 2023), 219 in a community specialist–care clinic, and 496 in 25 primary-care clinics. The overall cohort was predominantly male (60%), with a mean age of 73.5 years (± 10.7), and 60% with HF with reduced ejection fraction. In patients with ≥ 6 months of follow-up (n = 267), pre vs post annualized rates of HF-related acute health-service use decreased from 36.3 to 8.5 hospitalizations per 100 patients per year, <em>P</em> &lt; 0.0001, from 31.8 to 13.1 emergency department visits per 100 patients per year, <em>P</em> &lt; 0.0001, and from 152.8 to 110.0 urgent physician visits per 100 patients per year, <em>P</em> = 0.0001. The level of concordance with GDMT improved; the number of patients receiving triple therapy and quadruple therapy increased by 10.1% (95% confidence interval [CI], 2.4%,17.8%) and 19.6% (95% CI, 12.0%, 27.3%), respectively. Within these groups, optimal dosing was achieved in 42.5% (95% CI, 32.0%, 53.6%) and 35.0% (95% CI, 23.1%, 48.4%), respectively. In patients with at least one follow-up visit (n = 286), &gt; 50% experienced a clinically relevant improvement in their quality of life.</p></div><div><h3>Conclusions</h3><p>A community-based IDM program for HF, may reduce HF-related acute health-service use, improve quality of life and level of concordance with GDMT. These encouraging preliminary outcomes from a real-world program evaluation require confirmation in a randomized controlled trial.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001707/pdfft?md5=eef62f253480ea5e893401dd4379201c&pid=1-s2.0-S2589790X24001707-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140788284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Ventricular Tachycardia in a Postoperative Patient","authors":"Stephen A. Duffett MD ,&nbsp;Marko Balan MD ,&nbsp;Frédéric L. Paulin MD ,&nbsp;Sean P. Connors MD, DPhil","doi":"10.1016/j.cjco.2024.04.001","DOIUrl":"10.1016/j.cjco.2024.04.001","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X2400146X/pdfft?md5=ac18f73761e6f8b0ef8a4ea92f81399e&pid=1-s2.0-S2589790X2400146X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring Cardiovascular Disease in Métis Citizens Across Ontario, 2012-2020","authors":"Sabastian Koprich HBSc ,&nbsp;Shelley Cripps BSc ,&nbsp;Abigail J. Simms MPH ,&nbsp;Noel Tsui MPH ,&nbsp;Sarah A. Edwards PhD ,&nbsp;Stephanie W. Tobin PhD","doi":"10.1016/j.cjco.2024.03.014","DOIUrl":"10.1016/j.cjco.2024.03.014","url":null,"abstract":"<div><h3>Background</h3><p>Population-based analyses of Métis-specific health outcomes in Canada are limited. This study aimed to address this gap and examine cardiovascular disease outcomes in citizens of the Métis Nation of Ontario (MNO) over a 9-year period.</p></div><div><h3>Methods</h3><p>Under a data governance and sharing agreement between the MNO and ICES, registered MNO citizens aged ≥ 20 years were linked to administrative health data in Ontario. Existing algorithms were used to determine the burden of heart failure and hypertension. In the most recent year, prevalence rates were compared for income quintiles, age, and sex.</p></div><div><h3>Results</h3><p>Age-adjusted prevalence rates of hypertension decreased, and age-adjusted prevalence rates of heart failure increased in MNO citizens from 2012 to 2020. A larger decrease in prevalence of hypertension was observed for female citizens, by 12% from 28.9 per 100 (confidence interval [CI]: 27.6-30.2) in 2012 to 25.4 per 100 (CI: 24.5-26.3) in 2020. As for heart failure, the age-adjusted prevalence rates for male citizens had the largest increase, by 47% from 2.6 per 100 (CI: 2.1-3.1) in 2012 to 3.8 per 100 (CI: 3.3-4.2) in 2020. Hypertension and heart failure were more prevalent in male citizens, those of advanced age, and those living in areas within the lowest income quintile.</p></div><div><h3>Conclusions</h3><p>This study is the first in nearly 10 years to investigate trends in cardiovascular outcomes among MNO citizens. Understanding this burden is critical to the MNO’s ability to guide program and policy planning, as well as to advocate within and beyond the health system for Métis-specific needs.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001471/pdfft?md5=bb5df1716726290760d267a3875d226d&pid=1-s2.0-S2589790X24001471-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140773114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Flaxseed Compared to ACE Inhibition in Treating Anthracycline- and Trastuzumab-Induced Cardiotoxicity","authors":"Sara M. Telles-Langdon BKin (Hons), MSc ,&nbsp;Vibhuti Arya BSc (Hons), MSc ,&nbsp;Paris R. Haasbeek ,&nbsp;David Y.C. Cheung BSc ,&nbsp;Cameron R. Eekhoudt BSc, MSc ,&nbsp;Lana Mackic BSc ,&nbsp;Ashley N. Bryson BSc, MD ,&nbsp;Sonu S. Varghese BSc, MSc ,&nbsp;J. Alejandro Austria ,&nbsp;James A. Thliveris PhD ,&nbsp;Harold M. Aukema PhD ,&nbsp;Amir Ravandi MD, PhD, FRCPC ,&nbsp;Pawan K. Singal PhD, DSc, LLD (Hon) ,&nbsp;Davinder S. Jassal MD, FACC, FCCS, FRCPC","doi":"10.1016/j.cjco.2024.03.009","DOIUrl":"10.1016/j.cjco.2024.03.009","url":null,"abstract":"<div><h3>Background</h3><p>Although the current combination of surgery, radiation, and chemotherapy is used in the breast-cancer setting, the administration of the anticancer drugs doxorubicin and trastuzumab is associated with an increased risk of developing heart failure. The aim of this study is to determine whether dietary flaxseed is comparable and/or synergistic with the angiotensin-converting enzyme inhibitor perindopril in the treatment of doxorubicin- and trastuzumab-mediated cardiotoxicity.</p></div><div><h3>Methods</h3><p>In a chronic <em>in vivo</em> murine model (n = 110), doxorubicin and trastuzumab (8 mg/kg and 3 mg/kg, respectively) were administered weekly for 3 weeks. Following this period, the mice were randomized to daily consumption of a 10% flaxseed supplemented diet, administration of perindopril (3 mg/kg) via oral gavage, or a combination of both flaxseed and perindopril for an additional 3 weeks.</p></div><div><h3>Results</h3><p>In mice treated with doxorubicin and trastuzumab, the left ventricular ejection fraction decreased from 74% ± 4% at baseline to 30% ± 2% at week 6. Treatment with either flaxseed or perindopril, or with flaxseed and perindopril improved left ventricular ejection fraction to 52% ± 4%, 54% ± 4%, and 55% ± 3%, respectively (<em>P</em> &lt; 0.05). Although histologic analyses confirmed significant loss of sarcomere integrity and vacuolization in the doxorubicin- and trastuzumab-treated mice, treatment with flaxseed or perindopril, or with flaxseed and perindopril improved myocyte integrity. Finally, the level of Bcl-2 interacting protein 3, high-mobility group box 1 protein expression, and the levels of select oxylipins, were significantly elevated in mice receiving doxorubicin and trastuzumab; these markers were attenuated by treatment with either flaxseed or perindopril, or with flaxseed and perindopril.</p></div><div><h3>Conclusions</h3><p>Flaxseed was equivalent to perindopril at improving cardiovascular remodelling by reducing biomarkers of inflammation, mitochondrial damage, and cell death.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001410/pdfft?md5=efb4d21b630302479bd7e8a6c293131d&pid=1-s2.0-S2589790X24001410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140405644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Learning From Our Strengths: Exploring Strategies to Support Heart Health in Indigenous Communities","authors":"Sahr Wali PhD ,&nbsp;Elizabeth C. Hiscock MPH ,&nbsp;Anne Simard MHSc ,&nbsp;Nicole Fung ,&nbsp;Heather Ross MHSc, MD, FRCPC ,&nbsp;Angela Mashford-Pringle PhD","doi":"10.1016/j.cjco.2023.06.005","DOIUrl":"10.1016/j.cjco.2023.06.005","url":null,"abstract":"<div><p>Indigenous populations have remained resilient in maintaining their unique culture and values, despite facing centuries of colonial oppression. With many discriminatory policies continuing to disempower Indigenous peoples, First Nations communities have been reported to experience a higher level of cardiovascular disease (CVD)-related mortality, compared to that in the general population. Many of the risk factors contributing to the burden of CVD have been attributed to the impact of colonization and the ongoing dismissal of Indigenous knowledge. Despite Indigenous peoples recognizing the value of addressing their mental, physical, spiritual, and emotional well-being in balanced totality, current health services focus predominantly on the promotion of Western biomedicine. To begin to move toward reconciliation, a better understanding of how Indigenous health is defined within different cultural worldviews is needed. The objective of this scoping review was to explore the various Western and/or Indigenous strategies used for the prevention of CVD and the management of heart health and wellness in Indigenous communities in Canada. In this review, a total of 3316 articles were identified, and only 21 articles met the eligibility criteria. Three major themes emerged, as follows: (i) valuing of the emotional domain of health through cultural safety; (ii) community is at the core of empowering health outcomes; and (iii) bridging of cultures through partnership and mutual learning. Most studies recognized the importance of community engagement to develop heart health strategies that integrate traditional languages and cultures. However, to move toward the delivery of culturally safe care, health systems need to rebuild their relationship with Indigenous peoples.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X23001488/pdfft?md5=1482f44b716232b95663925d7c4ee417&pid=1-s2.0-S2589790X23001488-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42209372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Coronary Syndrome During the Era of COVID-19: Perspective and Implications Using Google Trends","authors":"Juan A. Quintero-Martinez MD ,&nbsp;Joaquin Espinoza MD ,&nbsp;Diego Celli MD ,&nbsp;Carlos Vergara-Sanchez MD ,&nbsp;Jonathan Salter MD ,&nbsp;William Aitken MD ,&nbsp;Igor Palacios MD ,&nbsp;Mauricio G. Cohen MD ,&nbsp;Pablo Rengifo-Moreno MD ,&nbsp;Eduardo de Marchena MD ,&nbsp;Rosario Colombo MD ,&nbsp;Carlos E. Alfonso MD ,&nbsp;George R. Marzouka MD","doi":"10.1016/j.cjco.2024.03.002","DOIUrl":"10.1016/j.cjco.2024.03.002","url":null,"abstract":"<div><h3>Background</h3><p>Acute coronary syndrome (ACS) hospital admissions decreased during the start of the COVID-19 outbreak. Information is limited on how Google searches were related to patients' behaviour during this time.</p></div><div><h3>Methods</h3><p>We examined de-identified data from 2019 through 2020 regarding the following monthly items: (i) admissions for ACS from the Veterans Affairs Healthcare System; (ii) out-of-hospital cardiac arrest (OHCA) from the National Emergency Medical Services Information System (NEMSIS) public dataset; and (iii) Google searches for “chest pain,” “coronavirus,” “chest pressure,” and “hospital safe” from Google Trends. We analyzed the trends for ACS admissions, OHCA, and Google searches.</p></div><div><h3>Results</h3><p>During the early months of the first COVID-19 outbreak, the following occurred: (i) Veterans Affairs data showed a significant reduction in ACS admissions at a national and regional (Florida) level; (ii) the NEMSIS database showed a marked increase in OHCA at a national level; and (iii) Google Trends showed a significant increase in the before-mentioned Google searches at a national and regional level.</p></div><div><h3>Conclusions</h3><p>ACS hospital admissions decreased during the beginning of the pandemic, likely owing to delayed healthcare utilization secondary to patients fear of acquiring a COVID-19 infection. Concordantly, the volume of Google searches for hospital safety and ACS symptoms increased, along with OHCA events, during the same time. Our results suggest that Google Trends may be a useful tool to predict patients’ behaviour and increase preparedness for future events, but statistical strategies to establish association are needed.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001331/pdfft?md5=49405c9c1af7dff50f557982fff4cd42&pid=1-s2.0-S2589790X24001331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140270919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}